Loading…
Employees: 1,188
Size Beijing Beilu Pharmaceutical (300016.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $692M, the 3085th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.94 on 6 Nov 2026.
Performance Over six months the shares fell 16.2%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 23.5% over the last twelve months (peer median +10.1%); the operating margin is 10.7% (peer median 11.5%).
Valuation It trades at 88.2× forward earnings against a peer median of 15.2× (most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (6.9% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.39B | CN¥1.20B | CN¥977M | CN¥886M | CN¥760M |
| Revenue growth | — | +23% | +10% | +17% | — |
| Gross profit | CN¥642M | CN¥513M | CN¥428M | CN¥382M | CN¥385M |
| EBITDA | n/a | CN¥182M | CN¥150M | CN¥63.0M | CN¥94.6M |
| Net income | CN¥162M | CN¥92.7M | CN¥13.7M | -CN¥71.8M | CN¥11.3M |
| Free cash flow | CN¥102M | -CN¥42.0M | CN¥74.8M | -CN¥82.1M | CN¥37.4M |
| Capital expenditure | CN¥141M | CN¥219M | CN¥101M | CN¥145M | CN¥103M |
| Total debt | CN¥531M | CN¥607M | CN¥881M | CN¥822M | CN¥701M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300016.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.5% | -4.0% | 3rd lowest of 21 |
| 6-month return | -16.2% | -5.6% | 8th lowest of 21 |
| Distance from 52-week high | -30.2% | -23.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +23.5% | +10.1% | 5th highest of 17 |
| Operating margin | 10.7% | 11.5% | 8th lowest of 16 |
| Forward P/E | 88.2× | 15.2× | most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 10.3% | 10.5% | 5th least demanding of 10 |
| Growth delivered (Del g) | +7.9% | +10.1% | 5th lowest of 10 |
| Hurdle (Req g minus delivered) | +2.5 pp | +15.6 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | -0.3 pp | -3.2 pp | 7th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |